Compare Nerdwallet Inc (NRDS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Novo Nordisk A/S — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $598.32M), while Novo Nordisk A/S trades at $45.08 (market cap $198.57B). The key difference: Novo Nordisk A/S is far larger — about 331.9× Nerdwallet Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | NVO | |
|---|---|---|
Market Cap | $598.32M | $198.57B |
Sector | Financials | Health |
52-Week High | $15.93 | $63.98 |
52-Week Low | $7.58 | $35.29 |
Enterprise Value | $512.62M | $213.37B |
Dividend Yield | — | 4.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.56, down 3.24% today, amid a bearish technical signal. The stock shows strong fundamentals with a low P/E of 10.4 and P/S of 0.78, alongside robust revenue growth from $539M in 2022 to $837M in 2025. Recent Q2 2026 earnings missed estimates at $0.07 per share, but Q1 and Q4 2025 beat expectations. Operating cash flow improved to $132M in 2025, though net cash flow turned negative in 2026 projections.
Outlook is mixed: valuation metrics suggest upside potential, with a 66.7% analyst buy rating and a 27.9% price target upside per Zacks (August 10, 2026). However, technical weakness and Q2 earnings miss pose near-term risks. Key catalysts include continued revenue growth and margin expansion, but reliance on organic search traffic remains a headwind.
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
